NasdaqCM - Nasdaq Real Time Price USD

Curis, Inc. (CRIS)

Compare

3.1900

-0.1700

(-5.06%)

At close: January 14 at 4:00:02 PM EST

3.1700

-0.02

(-0.63%)

After hours: January 14 at 6:15:44 PM EST

Curis Announces Additional Data from TakeAim Leukemia Study

Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday presented data from the TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) at the 66th ASH annual meeting.

PR Newswire last month

CRIS
-5.06%
Curis Third Quarter 2024 Earnings: Beats Expectations

Curis ( NASDAQ:CRIS ) Third Quarter 2024 Results Key Financial Results Revenue: US$2.93m (up 3.5% from 3Q 2023). Net...

Simply Wall St. last month

CRIS
-5.06%
Q3 2024 Curis Inc Earnings Call

Q3 2024 Curis Inc Earnings Call

Thomson Reuters StreetEvents last month

CRIS
-5.06%
Curis Inc (CRIS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...

Curis Inc (CRIS) reports reduced net loss and promising clinical trial results, while addressing financial and regulatory hurdles.

GuruFocus.com last month

CRIS
-5.06%
Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of 9.57% and 3.20%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

CRIS
-5.06%
Curis: Q3 Earnings Snapshot

LEXINGTON, Mass. AP) — Curis Inc. CRIS) on Thursday reported a loss of $10.1 million in its third quarter.

Associated Press Finance last month

CRIS
-5.06%
Curis Provides Third Quarter 2024 Business Update

Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the quarter ended September 30, 2024.

PR Newswire last month

CRIS
-5.06%
Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET.

PR Newswire 2 months ago

CRIS
-5.06%
Curis price target lowered to $20 from $26 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Curis (CRIS) to $20 from $26 and keeps a Buy rating on the shares. The firm cites dilution from this week’s registered direct offering for the target cut. Additional data from the TakeAim lymphoma study is expected in December and in Q1 of 2025, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts

TipRanks 2 months ago

CRIS
-5.06%
Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement

Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into a definitive agreement with a combination of existing and new investors for the purchase of 2,398,414 shares of its common stock in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Curis also agreed to issue to the investors in the reg

PR Newswire 2 months ago

CRIS
-5.06%
Curis Inc (CRIS) Q2 2024 Earnings Call Highlights: Promising Clinical Progress Amid Financial ...

Curis Inc (CRIS) reports significant advancements in lymphoma and leukemia treatments, despite rising expenses and a net loss for the quarter.

GuruFocus.com 3 months ago

CRIS
-5.06%
Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced the 3rd Annual Symposium on IRAK4 in Cancer taking place virtually on September 26, 9:00 AM-1:00 PM E.T.

PR Newswire 3 months ago

CRIS
-5.06%
Curis to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference later today at 4:15 PM ET. Details for the webcast can be found using the Cantor webcast link.

PR Newswire 3 months ago

CRIS
-5.06%
Curis to Present at Upcoming Healthcare Conferences in September

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences:

PR Newswire 4 months ago

CRIS
-5.06%
Analysts' Revenue Estimates For Curis, Inc. (NASDAQ:CRIS) Are Surging Higher

Celebrations may be in order for Curis, Inc. ( NASDAQ:CRIS ) shareholders, with the analysts delivering a significant...

Simply Wall St. 5 months ago

CRIS
-5.06%
Earnings Update: Curis, Inc. (NASDAQ:CRIS) Just Reported And Analysts Are Boosting Their Estimates

It's been a mediocre week for Curis, Inc. ( NASDAQ:CRIS ) shareholders, with the stock dropping 18% to US$5.00 in the...

Simply Wall St. 5 months ago

CRIS
-5.06%
Curis Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Curis ( NASDAQ:CRIS ) Second Quarter 2024 Results Key Financial Results Revenue: US$2.55m (up 16% from 2Q 2023). Net...

Simply Wall St. 5 months ago

CRIS
-5.06%
Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of -19.41% and 15.73%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

CRIS
-5.06%
Curis: Q2 Earnings Snapshot

LEXINGTON, Mass. AP) — Curis Inc. CRIS) on Thursday reported a loss of $11.8 million in its second quarter.

Associated Press Finance 5 months ago

CRIS
-5.06%
Curis Provides Second Quarter 2024 Financial and Operating Update

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its financial and operating results for the second quarter ended June 30, 2024.

PR Newswire 5 months ago

CRIS
-5.06%

Performance Overview

Return	CRIS	S&P 500
YTD	+1.59%	-1.08%
1-Year	-75.08%	+22.14%
3-Year	-7.00%	+25.41%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Curis, Inc. (CRIS)

Curis Announces Additional Data from TakeAim Leukemia Study

Curis Third Quarter 2024 Earnings: Beats Expectations

Q3 2024 Curis Inc Earnings Call

Curis Inc (CRIS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...

Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates

Curis: Q3 Earnings Snapshot

Curis Provides Third Quarter 2024 Business Update

Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024

Curis price target lowered to $20 from $26 at H.C. Wainwright

Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement

Curis Inc (CRIS) Q2 2024 Earnings Call Highlights: Promising Clinical Progress Amid Financial ...

Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer

Curis to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare Conference

Curis to Present at Upcoming Healthcare Conferences in September

Analysts' Revenue Estimates For Curis, Inc. (NASDAQ:CRIS) Are Surging Higher

Earnings Update: Curis, Inc. (NASDAQ:CRIS) Just Reported And Analysts Are Boosting Their Estimates

Curis Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates

Curis: Q2 Earnings Snapshot

Curis Provides Second Quarter 2024 Financial and Operating Update

Performance Overview